Phase II Assessment of Recombinant Leukocyte A Interferon with Difluoromethylornithine in Disseminated Malignant Melanoma
- 1 June 1990
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 13 (3), 218-220
- https://doi.org/10.1097/00000421-199006000-00008
Abstract
Sixteen patients with advanced melanoma received IFN-.alpha.2A, 36 .times. 106 U/m2 i.m., on days 3-7 with 2.25 g/m2 DFMO p.o. on days 1-7. We observed no objective regressions. Median time to progression was 1.2 months with a median survival of 5.2 months. A flu-type syndrome was the predominant sequela. From the dose and schedule that we utilized, this regimen holds little promise against disseminated malignant melanoma.This publication has 7 references indexed in Scilit:
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Recombinant Interferons in the Management of Advanced Malignant Melanoma Updated Review of Five Prospective Clinical Trials and Long-Term RespondersAmerican Journal of Clinical Oncology, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Recombinant leukocyte a interferon (rIFN-αA) in the treatment of disseminated malignant melanoma: Analysis of complete and long-term responding patientsCancer, 1986
- Tumor Suppression with a Combination of α-Difluoromethyl Ornithine and InterferonScience, 1983
- NEW DRUGS IN OVARIAN-CANCER AND MALIGNANT-MELANOMA - INVITRO PHASE-II SCREENING WITH THE HUMAN-TUMOR STEM-CELL ASSAY1981
- Evaluation of response criteria in advanced lung cancerCancer, 1979